BMS secures US FDA approval for Breyanzi to treat B-cell Lymphoma
Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in TRANSCEND NHL 001 trial
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Feb 21
Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in TRANSCEND NHL 001 trial
05 Feb 21
The drugmaker claims that Forxiga is the first SGLT2 inhibitor approved in China to treat heart failure with…
02 Feb 21
Plegridy intramuscular injection offers a treatment option with reduced injection site reactions for individuals with relapsing multiple sclerosis…
27 Jan 21
AstraZeneca said its Symbicort Turbuhaler is the first approved dual-combination therapy for mild, moderate and severe asthma in…
25 Jan 21
The FDA approval of the combination regimen is based on the results of the phase 3 CheckMate -9ER…
25 Jan 21
Pfizer and BioNTech's Covid-19 vaccine has been provisionally approved for individuals aged 16 years and above
22 Jan 21
ViiV Healthcare said that Cabenuva is the first and only complete long-acting regimen for the treatment of HIV-1…
21 Jan 21
Merck claimed that its Verquvo is the first soluble guanylate cyclase stimulator to receive FDA approval for the…
21 Jan 21
EC approval is based on results from Phase 2 DESTINY-Breast01 trial, which showed clinically meaningful and durable responses
19 Jan 21
The companies claimed that their Enhertu is the first HER2-directed medicine approved for patients with gastric cancer in…